<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 20, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6010414/global-protac-targeted-protein-degraders-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=l3gdv7&amp;utm_campaign=2330894+-+Global+PROTAC+Targeted+Protein+Degraders+Market+Outlook+2026-2030%3a+Covers+Indications%2c+Trial+Phases%2c+Combinations%2c+and+Technology+Platforms&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Global PROTAC Targeted Protein Degraders Market Opportunity, Approved Drug Sales, Pricing, Technology Platforms, &amp; Clinical Trials Insight 2030">"Global PROTAC Targeted Protein Degraders Market Opportunity, Approved Drug Sales, Pricing, Technology Platforms, &amp; Clinical Trials Insight 2030"</a> has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of commercial opportunities, approved drug sales, pricing trends, proprietary technology platforms, clinical trials and the competitive landscape through 2030. The global market opportunity is projected to exceed USD 1.50 billion by 2030, supported by expanding clinical pipelines, strategic collaborations and continued investment in targeted protein degradation. Report Findings and Highlights: <ul><li>Global PROTAC targeted protein degraders market opportunity exceeding USD 1.50 billion by 2030</li><li>Comprehensive analysis of more than 140 PROTAC drugs in clinical development</li><li>Clinical trial intelligence segmented by company, country, indication and development phase</li><li>Fast Track and Orphan Drug designation analysis</li><li>Regional and indication-specific PROTAC market trends</li><li>Assessment of proprietary targeted protein degradation technology platforms</li><li>Approved drug sales and pricing analysis</li><li>Competitive landscape, partnerships, licensing agreements and investment activity</li></ul> PROTAC Targeted Protein Degradation Market Outlook Targeted protein degradation has become an important area of pharmaceutical research, with potential applications across oncology, immunology, neuroscience, infectious diseases and other therapeutic fields. Advances in medicinal chemistry, structural biology, computational drug discovery, linker optimization and E3 ligase biology have accelerated the transition of PROTAC technology from academic research into clinical and commercial development. The report examines the global PROTAC market landscape, including drug discovery strategies, clinical development programs, technology platforms, competitive positioning, commercial prospects and partnering activity. It also evaluates the roles of pharmaceutical companies, biotechnology firms, universities, contract research organizations and technology providers in shaping the future of targeted protein degradation. Emerging opportunities related to investment, licensing, strategic partnerships and portfolio expansion are assessed to support pharmaceutical executives, biotechnology companies, investors and other stakeholders evaluating the growing precision medicine market. PROTAC Clinical Trials and Drug Pipeline Analysis Clinical development remains a critical indicator of the long-term commercial potential of PROTAC therapies. More than 140 drug candidates are reviewed across clinical and development-stage pipelines, with analysis covering indications, molecular targets, sponsors, mechanisms, development phases and geographic distribution. The report evaluates monotherapy and combination therapy strategies in oncology and other therapeutic areas. Combination programs involving endocrine therapies, kinase inhibitors, immunotherapies, targeted treatments, chemotherapy and emerging drug modalities are examined, particularly where developers aim to improve efficacy or address treatment resistance. Additional analysis identifies the companies and organizations sponsoring, developing and conducting preclinical and clinical studies. This coverage provides a structured view of the global PROTAC clinical ecosystem and highlights the programs, targets and indications expected to influence future market growth. Competitive Landscape and Leading PROTAC Companies The competitive environment includes multinational pharmaceutical companies, specialized biotechnology firms, contract research organizations and leading academic institutions. Developers are advancing proprietary platforms focused on novel E3 ligases, tissue-specific degraders, brain-penetrant compounds and next-generation protein degradation technologies. Investment is also expanding across enabling technologies, including artificial intelligence, computational drug design, proteomics, structural biology, ligand discovery and biomarker development. Licensing agreements, research collaborations, venture financing and acquisitions continue to strengthen the commercial potential of the sector while accelerating innovation across multiple disease areas. Technology Platforms, Collaborations and Licensing Agreements Proprietary discovery platforms are becoming key competitive differentiators in the PROTAC market. These platforms integrate medicinal chemistry, computational modeling, structural biology, ligand discovery, linker design, artificial intelligence, proteomics, pharmacokinetic modeling and E3 ligase research to improve degrader discovery and optimization. Arvinas' PROTAC Discovery Engine is among the prominent platforms assessed in the report. Its integrated capabilities span target biology, E3 ligase expertise, high-throughput chemistry, structural biology, ligand discovery and translational pharmacology. The broader report compares company platforms, pipeline productivity, clinical progress and partnership strategies. Strategic collaborations among pharmaceutical companies, biotechnology developers, academic laboratories, artificial intelligence specialists and contract research organizations are expected to remain central to innovation. These alliances combine expertise in target discovery, medicinal chemistry, biomarker development, clinical execution and precision medicine. Future Direction of PROTAC Therapies Future growth is expected to extend beyond first-generation oncology programs. New E3 ligases, tissue-selective degradation, central nervous system delivery, improved oral bioavailability, optimized pharmacodynamic profiles and biomarker-based patient selection may broaden the clinical application of PROTAC therapies. The report also examines molecular glues, artificial intelligence-enabled degrader discovery and advanced delivery technologies. By integrating scientific progress with market forecasts, pricing, approved drug sales, investment trends and partnership strategies, the analysis provides a detailed view of the factors expected to define the global PROTAC targeted protein degraders market through 2030. Key Topics Covered 1. Introduction To PROTAC Technology 1.1 Overview Of PROTAC Technology 1.2 Development &amp; Evolution of PROTACs 2. PROTAC Therapies Potential In Cancer Therapeutics 2.1 Importance As Targeted Therapy 2.2 Comparison With Conventional Treatment Methods 3. Clinical Overview of PROTAC Technology 3.1 Components Of PROTAC Molecules 3.2 Mechanism Of Action 4. FDA Approved PROTAC: Veppanu (Vepdegestrant) - Clinical &amp; Pricing insight 4.1 Overview &amp; Patent Insight 4.2 Pricing &amp; Dosing 5. Global PROTAC Drugs Clinical Trials Insight Overview 5.1 by Company 5.2 by Country 5.3 by Phase 5.4 by Indication 6. Global PROTAC Drugs Clinical Trials Insight by Company, Country, Indication &amp; Phase 6.1 Research 6.2 Preclinical 6.3 Phase I 6.4 Phase I/II 6.5 Phase II 6.6 Phase III 7. Marketed PROTAC Drugs Clinical Trials Insight by Company, Country &amp; Indication 8. PROTAC Technology Platforms by Companies 9. Global PROTAC Drug Market Trends Insight 9.1 Current Market Overview 9.2 Future Clinical &amp; Commercial Opportunities 10. Global PROTAC Drug Market Trends by Region 10.1 US 10.2 South Korea 10.3 China 11. Global PROTAC Drug Market Trends by Indication 11.1 Cancer 11.2 Autoimmune &amp; Inflammatory Diseases 11.3 Infectious Diseases 11.4 Neurodegenerative Diseases 11.5 Cardiovascular Diseases 12. Global PROTAC Drugs Market Dynamics &amp; Outlook 12.1 Drivers &amp; Opportunities 12.2 Challenges &amp; Restraints 13. Competitive Landscape 13.1 Arvinas 13.2 Axter Therapeutics 13.3 Beactica 13.4 BioTheryX 13.5 BeOne Medicines 13.6 EnhancedBio 13.7 InSilico Medicine 13.8 Suzhou Kintor Pharmaceuticals 13.9 Ubix Therapeutics 13.10 Uppthera For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6010414/global-protac-targeted-protein-degraders-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=l3gdv7&amp;utm_campaign=2330894+-+Global+PROTAC+Targeted+Protein+Degraders+Market+Outlook+2026-2030%3a+Covers+Indications%2c+Trial+Phases%2c+Combinations%2c+and+Technology+Platforms&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/mov6w2</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/N2E1NzBiYmMtMjY3Ni00NzM3LThmYWMtZjRkNzk3YTA0MTJmLTEwMjY3MzctMjAyNi0wOC0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Global PROTAC Targeted Protein Degraders Market Outlook 2026-2030: Covers Indications, Trial Phases, Combinations, and Technology Platforms

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn